|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009324,
umls-concept:C0013058,
umls-concept:C0031336,
umls-concept:C0034656,
umls-concept:C0035020,
umls-concept:C0087111,
umls-concept:C0525033,
umls-concept:C0599724,
umls-concept:C1442989,
umls-concept:C1553890,
umls-concept:C1831848,
umls-concept:C2825951
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-10-7
|
|
pubmed:abstractText |
VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end point of the study was to assess the effects of supplementation with VSL#3 in patients affected by relapsing ulcerative colitis (UC) who are already under treatment with 5-aminosalicylic acid (ASA) and/or immunosuppressants at stable doses.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1572-0241
|
|
pubmed:author |
pubmed-author:AnneseVitoV,
pubmed-author:BrandimarteGiovanniG,
pubmed-author:D'AmicoTeresaT,
pubmed-author:DaneseSilvioS,
pubmed-author:Di GiulioEmilioE,
pubmed-author:Di RosaSalvatoreS,
pubmed-author:EliseiWalterW,
pubmed-author:FortiGiacomoG,
pubmed-author:GasbarriniAntonioA,
pubmed-author:GiglioAndreaA,
pubmed-author:GiorgettiGian MarcoGM,
pubmed-author:HassanCesareC,
pubmed-author:ImeneoMariaM,
pubmed-author:LarussaTizianaT,
pubmed-author:LuzzaFrancescoF,
pubmed-author:ModeoMaria EsterME,
pubmed-author:MoriniSergioS,
pubmed-author:PapaAlfredoA,
pubmed-author:PistoiaMaria AntoniettaMA,
pubmed-author:Rodino'StefanoS,
pubmed-author:Sacca'NataleN,
pubmed-author:SebkovaLadislavaL,
pubmed-author:TursiAntonioA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
105
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2218-27
|
|
pubmed:dateRevised |
2011-9-30
|
|
pubmed:meshHeading |
pubmed-meshheading:20517305-Adult,
pubmed-meshheading:20517305-Azathioprine,
pubmed-meshheading:20517305-Bifidobacterium,
pubmed-meshheading:20517305-Colitis, Ulcerative,
pubmed-meshheading:20517305-Combined Modality Therapy,
pubmed-meshheading:20517305-Double-Blind Method,
pubmed-meshheading:20517305-Female,
pubmed-meshheading:20517305-Humans,
pubmed-meshheading:20517305-Lactobacillus,
pubmed-meshheading:20517305-Male,
pubmed-meshheading:20517305-Mesalamine,
pubmed-meshheading:20517305-Middle Aged,
pubmed-meshheading:20517305-Patient Selection,
pubmed-meshheading:20517305-Probiotics,
pubmed-meshheading:20517305-Recurrence,
pubmed-meshheading:20517305-Remission Induction,
pubmed-meshheading:20517305-Severity of Illness Index,
pubmed-meshheading:20517305-Streptococcus thermophilus,
pubmed-meshheading:20517305-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
|
|
pubmed:affiliation |
"Lorenzo Bonomo" Hospital, Andria, Italy. antotursi@tiscali.it
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
